Traws Pharma, INC Schedule 13G passive stakes

Ikarian Capital, LLC and Neil Shahrestani have jointly filed a Schedule 13G, reporting beneficial ownership of 9.5% of Traws Pharma, Inc.'s common stock, including shares issuable upon warrant exercise.

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported zero beneficial ownership of Traws Pharma, Inc. common stock.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Traws Pharma, Inc. common stock.

Adage Capital Management, L.P. has disclosed a beneficial ownership of 730,000 shares, representing 4.79% of Traws Pharma, Inc.'s common stock, as of June 30, 2026.

Perceptive Advisors LLC and Joseph Edelman have reported a 6.1% beneficial ownership stake in Traws Pharma, Inc. through warrant holdings.

Squadron Master Fund LP, along with affiliated entities and individuals, has reported beneficial ownership of 511,714 shares, representing 6.4% of Traws Pharma, Inc.'s common stock.

Squadron Master Fund LP and its affiliates have disclosed an 8.9% beneficial ownership stake in Traws Pharma, Inc. common stock.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a 9.14% beneficial ownership stake in Traws Pharma, Inc.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have disclosed a 4.29% beneficial ownership stake in Traws Pharma, INC. through a Schedule 13G filing.

Jorey Chernett has reported a 6.8% beneficial ownership stake in Traws Pharma, Inc., holding 543,268 common shares as a passive investor.

Perceptive Advisors and affiliates report a 9.99% beneficial ownership stake in Traws Pharma, Inc., primarily through exercisable warrants, as detailed in their latest Schedule 13G filing.

Squadron Master Fund LP and related entities report beneficial ownership exceeding 5% in Traws Pharma, Inc. common stock.

Adage Capital Management, L.P. and its principals have reported a beneficial ownership of 4.67% of Traws Pharma, Inc.'s common stock as of September 30, 2025.

Squadron Capital Management and affiliated entities have reported a 6.0% beneficial ownership stake in Traws Pharma, Inc., totaling 420,501 shares.

Investment adviser Ikarian Capital, LLC and Neil Shahrestani have disclosed a combined beneficial ownership of 9.99% of Traws Pharma, Inc.'s common stock, including shares acquirable via warrants.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 9.99% beneficial ownership stake in Traws Pharma, Inc., totaling 545,197 shares.

Adage Capital Management, L.P. and its principals have disclosed a passive 6.5% beneficial ownership stake in Traws Pharma, Inc., holding 330,000 shares of common stock.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has reported a 9.9% beneficial ownership stake in Traws Pharma, Inc., totaling 302,252 shares as of December 31, 2024.

Investment firm Ikarian Capital, LLC and its sole manager Neil Shahrestani have disclosed a 9.99% beneficial ownership stake in Traws Pharma, Inc., including shares acquirable through warrants.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have jointly disclosed a 9.9% beneficial ownership stake in Traws Pharma, INC., primarily through warrants.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a passive beneficial ownership of 9.9% in Traws Pharma, Inc.'s common stock.